What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?

Area of Science:

• Oncology
• Endocrinology
• Breast Cancer Research

Background:

• Growing interest in neoadjuvant endocrine therapy (NET) for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.
• Genomic assays reveal many HR+/HER2- patients do not benefit from chemotherapy, increasing NET's appeal as a less toxic option.
• NET is known for tumor downsizing and breast conservation, but axillary surgery guidelines remain unclear.

Purpose of the Study:

• To review primary endocrine therapy for HR+/HER2- breast cancer.
• To examine landmark clinical trials investigating neoadjuvant endocrine therapy.
• To discuss the management of residual nodal disease after NET.

Main Methods:

• Literature review of primary endocrine therapy.
• Analysis of landmark clinical trials in neoadjuvant endocrine therapy.
• Synthesis of current approaches to managing nodal disease post-NET.

Main Results:

• Neoadjuvant endocrine therapy is an effective strategy for tumor reduction in HR+/HER2- breast cancer.
• Clinical trials demonstrate the efficacy of NET in specific patient populations.
• Management of residual nodal disease requires further definition and standardization.

Conclusions:

• Neoadjuvant endocrine therapy is a viable and less toxic treatment option for HR+/HER2- breast cancer.
• Further research is needed to refine axillary surgery algorithms following NET.
• Standardized protocols for managing residual nodal disease are essential for optimal patient outcomes.